Leukeran (chlorambucil) / GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...6789101112131415161718»
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Shifting Treatment Patterns and Clinical Outcomes in Veterans Diagnosed with Waldenstrom Macroglobulinemia from 2006 to 2018 (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2524;    
    Over the last decade, several treatments have been introduced into the WM therapeutics landscape including, bendamustine, bortezomib, and most recently oral Bruton’s kinase inhibitor (ibrutinib)...However, the median immunoglobulin M (IgM) was substantially lower in patient’s treated with ibrutinib (2,570 mg/dL [range: 422-9,001 mg/dL]) and single-agent rituximab (R), 2,855 mg/dL (range: 84-7,880 mg/dL) when compared to those treated with chlorambucil +/- rituximab (4,416 mg/dL [range: (9-8,130 mg/dL]) and bortezomib/dexamethasone +/- rituximab (BDR), 4,086 mg/dL (range: 16-9,944 mg/dL)...Hepatitis C testing occurred in 61 (19%) of patients, with testing most frequently occurring in patients treated with dexamethasone, rituximab, and cyclophosphamide (DRC), BDR, and BR...Limitations of this study include the differences observed in follow-up time as well as the limited number of patients in some 1L treatment groups. Further research is required to establish the long-term benefits and potential treatment-related toxicities of WM treatments in real-world clinical settings.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment. (Pubmed Central) -  Nov 3, 2020   
    Median overall survival (OS) has not been reached, being above 247 months; median OS for patients given CP was 115 months, for FC above 132 months and for FCR above 136 months (p > 0.5). CLL seems to be less aggressive in Mexican mestizos than in Caucasians; 43% of patients do not need treatment at all.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] A study of hematological disease prevalence in covid-19 pandemic: a single center experience () -  Oct 21, 2020 - Abstract #EHOC2020EHOC_253;    
    Alongside of particularly the elderly, the patient group with hematological conditions that are immunosuppressed due to conditions themselves or their treatment regimens are at particular risk of infection by the COVID-19 pandemic. Our study have shown that the prevalence of hematological conditions is about 0.5% among patients infected by COVID-19.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Chronic lymphocytic leukemia: diagnostic profile and treatment outcomes () -  Oct 17, 2020 - Abstract #SOHOItaly2020SOHO_Italy_23;    
    Our study have shown that the prevalence of hematological conditions is about 0.5% among patients infected by COVID-19. In our study CLL affected mostly males and elderly persons of 60-79 years old The majority of patients were diagnosed with stage A Autoimmune hemolytic anemia and infections turned out to be the relatively frequent complications of CLL The overall survival depended on CLL stage, and proved to be comparably increased under the combined treatment
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] NOT ALWAYS INDOLENT: A CASE OF PULMONARY MALT LYMPHOMA () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_1984;    
    Though it has been characterized as an indolent disease, our case confirms other recent reports that not all cases are benign. Specific treatment regimens as well as the importance of follow up should be carefully considered for patients with disseminated and recurrent pulmonary MALT lymphoma.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Atypical presentation of bilateral acute retinal necrosis in a Coronavirus disease 2019 positive immunosuppressed patient (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1382;    
    Acute retinal necrosis (ARN) is a very rare retinal disease with rates reported of approximately 0.5 new cases per million population.Here we present a case of an immunosuppressed patient, with viral retinitis, who was positive for COVID-19 but was systemically largely asymptomatic and vitreous PCR negative for COVID-19. To the best of our knowledge this is the first description of a case that has undergone vitreous PCR testing for COVID-19.
  • ||||||||||  Leustatin (cladribine) / J&J, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] New drugs for low grade lymphoproliferative diseases (ATİLLA YALÇIN HALL) -  Sep 23, 2020 - Abstract #EHOC2020EHOC_28;    
    Tazemetostat a novel EZH2 inhibitor recently received accelerated approval by FDA for patients with RR-FL and EZH2 gene mutations, following the results of a phase-II study...Immune check point inhibitors (Nivolumab, Pemprolizumab, Atezolizumab) are promising as third line treatment and beyond. Other agents under investigation include the inhibitor of nuclear export selinexor, the SYK inhibitor entospletinib, the dual SYK/JAK inhibitor certulatinib and the CDK inhibitors flavopiridol and dinaciclib.
  • ||||||||||  Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
    Trial completion date, Trial primary completion date:  GAIRI: Gazyva Infusion Reaction Investigation (clinicaltrials.gov) -  Sep 14, 2020   
    P=N/A,  N=104, Recruiting, 
    Terminated --> Completed Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Mar 2019 --> Aug 2024
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] BTK Inhibitors and Chemoimmunotherapy for CLL () -  Sep 14, 2020 - Abstract #SOHO2020SOHO_306;    
    The results from the MD Anderson iFCG and FILO studies suggest that these results may be achievable with lower total doses of chemotherapy, which may translate into lower risk of tMN in the future. An important future question will be whether similar results can be achieved with chemotherapy-free regimens (e.g., BTK inhibitors + venetoclax +/– CD20 antibodies) and whether these regimens will have the same potential to achieve durable remission and potential cure.
  • ||||||||||  tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    Review, Journal:  Prevention of complications from use of conventional immunosuppressants: a critical review. (Pubmed Central) -  Sep 11, 2020   
    For each category the possible side effects will be reviewed, the general and specific measures to prevent or treat the adverse events will be suggested, and the more common mistakes that may increase the risk of toxicity will be described. However, the efficacy and safety of immunosuppressive agents depend not only on the pharmacologic characteristics of single drugs but can be influenced also by the clinical condition and genetic characteristics of the patient, by the typology and severity of the underlying disease and by the interaction with other concomitantly used drugs.
  • ||||||||||  Benlysta (belimumab) / GSK, cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Sensitization of CLL cells for systemic therapy by neutralizing B cell activating factor (BAFF) using belimumab (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1872;    
    Taken together, our results define BAFF as critical mediator of CLL cell resistance to current treatment modalities. Based on our findings, we will evaluate BAFF neutralization with belimumab in a clinical trial combining belimumab with the standard treatment regime rituximab and venetoclax in patients with relapsed and refractory CLL.
  • ||||||||||  Benlysta (belimumab) / GSK, cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Sensitization of CLL cells for systemic therapy by neutralizing B cell activating factor (BAFF) using belimumab (Osaka) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1856;    
    Taken together, our results define BAFF as critical mediator of CLL cell resistance to current treatment modalities. Based on our findings, we will evaluate BAFF neutralization with belimumab in a clinical trial combining belimumab with the standard treatment regime rituximab and venetoclax in patients with relapsed and refractory CLL.
  • ||||||||||  Benlysta (belimumab) / GSK, cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Sensitization of CLL cells for systemic therapy by neutralizing B cell activating factor (BAFF) using belimumab (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1227;    
    Taken together, our results define BAFF as critical mediator of CLL cell resistance to current treatment modalities. Based on our findings, we will evaluate BAFF neutralization with belimumab in a clinical trial combining belimumab with the standard treatment regime rituximab and venetoclax in patients with relapsed and refractory CLL.
  • ||||||||||  Benlysta (belimumab) / GSK, cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Sensitization of CLL cells for systemic therapy by neutralizing B cell activating factor (BAFF) using belimumab (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_367;    
    Taken together, our results define BAFF as critical mediator of CLL cell resistance to current treatment modalities. Based on our findings, we will evaluate BAFF neutralization with belimumab in a clinical trial combining belimumab with the standard treatment regime rituximab and venetoclax in patients with relapsed and refractory CLL.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Obinutuzumab use complicated by progressive multifocal leukoencephalopathy: a case report. () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_339;    
    Obinutuzumab is a humanized anti-CD20 monoclonal antibody approved for use in combination with chlorambucil as treatment of chronic lymphocytic leukemia...However, most of these cases represent a carryover effect from previous rituximab therapy.Objectives To describe a case of non-carryover obinutuzumab PML occuring in a female patient with chronic lymphocytic leukemia.Methods A 76-year-old, HIV-negative female was admitted in our institution in May 2020 for evaluation of progressive cerebellar syndrome...Although the reported patient had a higher risk to develop PML resulting from the underlying predisposing disease (CLL), it is however conceivable that the introduction of obinutuzumab triggered JCV reactivation and development of PML in the reported case. Further investigations are needed to determine whether PML could be a class effect of anti-CD20 antibodies.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Review, Journal:  Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. (Pubmed Central) -  Aug 15, 2020   
    The long-term adverse effects of this treatment are not known. Comparative studies of CNIs, MMF, levamisole and alkylating agents have demonstrated little or no differences in efficacy but, because of insufficient power; clinically important differences in treatment effects have not been completely excluded.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    Journal:  Molecular characteristics of DNA-alkylating PI polyamides targeting RUNX transcription factors. (Pubmed Central) -  Aug 11, 2020   
    Conjugate 1 is a DNA-alkylating pyrrole-imidazole (PI) polyamide conjugate containing chlorambucil as an anticancer agent...Comparison of the characteristics of conjugates 1 and 2 suggested that reaction selectivity and binding affinity to the RUNX-binding sequence were improved by the introduction of -alanine. These findings indicate the potential of DNA-alkylating PI polyamides as candidates for cancer chemotherapeutics.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] What is Fitness in the Era of Targeted Agents? () -  Jul 14, 2020 - Abstract #SOHO2020SOHO_186;    
    The venetoclax-obinutuzumab combination has been specifically addressed to patients with coexisting conditions; patients were enrolled in the study if they had a total CIRS score > 6 or a CrCl < 70 mL/min...New target agents have changed the CLL standard of care; prospective studies evaluating patients outside clinical trials are needed to better define the prognostic value of CIRS and to determine the optimal approach towards those who have significant comorbidities. Another issue that should be considered when analyzing fitness and tolerability for targeted drugs is polypharmacy and drug interactions; none of the studies so far have analyzed their impact on treatment outcome.
  • ||||||||||  [VIRTUAL] More Than Meets the Eye: Bronchopulmonary Leukemic Infiltrates in Chronic Lymphocytic Leukemia (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6255;    
    He has a history of chronic lymphocytic leukemia (CLL) complicated by hypogammaglobulinemia on intravenous immunoglobulin, localized melanoma status post excision, and left breast carcinoma status post mastectomy, radiation therapy, and adjuvant anastrazole...After six weeks of treatment with voriconazole, his fevers persisted and CT of the chest demonstrated progressive patchy ground-glass opacities and nodular consolidation...Time limited CLL specific therapy with obinutuzumab/chlorambucil was initiated...It is important to differentiate a possible "passenger effect", which is a reactive, nonspecific recruitment of inflammatory cells into the lung parenchyma. An appropriate level of suspicion and a proper diagnosis can lead to discontinuation of antimicrobial therapy and initiation of CLL directed therapy.
  • ||||||||||  paclitaxel / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Sick to My Stomach⋯and Lungs! A Rare Case of Pulmonary Maltoma (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6216;    
    The patient was started on Gemcitabine and Paclitaxel, with an outpatient follow-up...Chemotherapy with rituximab-chlorambucil is considered first line...Blood. 2016;127(17):2082-92.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    [VIRTUAL] An Unusual Case of Asymptomatic Persistent Lung Infiltrates (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6158;    
    For symptomatic patient, chlorambucil-based chemotherapy is often the first choice...Despite stages of disease, MALT lymphoma has a good prognosis, with a 5-year and 10-year survival rate of 90% and 70% respectively. Follow-up visits every 3-6 months are recommended due to its high relapse rate.
  • ||||||||||  prednisolone / Generic mfg., Leukeran (chlorambucil) / GSK
    Clinical, Journal:  Rapid clinical progression of B-cell chronic lymphocytic leukemia in a horse. (Pubmed Central) -  Jul 4, 2020   
    This report was the first to describe the use of chemotherapy, albeit unsuccessful, for the treatment of B-cell CLL in a horse. This information should be useful for guiding expectations for prognosis and management of other horses affected with the disease.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    Journal:  B-cell chronic lymphocytic leukemia in a miniature American Eskimo dog. (Pubmed Central) -  Jul 4, 2020   
    Although cytologic evaluation of a lymph node aspirate was interpreted as lymphoma, a complete blood cell count, flow cytometric immunotyping of blood leukocytes, and serum electrophoresis identified B-cell chronic lymphocytic leukemia. Chemotherapy with chlorambucil was recommended.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    [VIRTUAL] Primary cutaneous aggressive epidermotropic cutaneous T-cell lymphoma () -  Jun 20, 2020 - Abstract #AADVMX2020AAD-VMX_127;    
    PCAECTCL is a rare, aggressive cutaneous lymphoma which may initially mimic CD8+ MF. Rapid progression of ulcerations should prompt consideration of this highly morbid condition and initiation of appropriate workup and Treatment.